Why Medtronic Is One of the Smartest Companies on the Planet
Leo Sun, The Motley Fool - Motley Fool - Sat Apr 19, 9:00AM CDT
MIT Tech Review recently named Medtronic one of of the 50 smartest companies of 2013, placing the 65-year-old medical device company side by side with much younger companies like Google , and...
Earnings Roundup: St. Jude's 1 Bright Spot
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
St. Jude 's tepid first-quarter results mask a quickening in sales for the company's atrial fibrillation products that shouldn't be ignored by investors. St. Jude has been boosting its atrial fibrillation, or AF, offering in anticipation of...
Final Glance: Medical Devices companies
AP - Thu Apr 17, 5:01PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Early Glance: Medical Devices companies
AP - Thu Apr 17, 10:31AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Boston Scientific To Host And Webcast Investor Event
PR Newswire - Thu Apr 17, 8:19AM CDT
Boston Scientific Corporation (NYSE: BSX) will host an investor event on May 8, 2014 to provide an update on company Cardiac Rhythm Management and Electrophysiology initiatives as well as developments and technologies in connection with its attendance at the 2014 Annual Heart Rhythm Society Scientific Session in San Francisco, CA. The event, which will include a question and answer session, is scheduled to begin at 5:00 p.m. PT and adjourn at approximately 6:30 p.m. PT.
Research and Markets: Global Drug-Eluting Stent Market 2014-2018 With Abbott Laboratories, Boston Scientific, Medtronic & Terumo Dominating
Business Wire - Thu Apr 17, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bj54l9/global) has announced the addition of the "Global Drug-eluting Stent Market 2014-2018 with Abbott Laboratories, Boston Scientific, Medtronic & Terumo Dominating" report to their offering.
Global Drug-eluting Stent Market 2014-2018 with Abbott Laboratories, Boston Scientific, Medtronic & Terumo Dominating
M2 - Thu Apr 17, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c6b9zf/global) has announced the addition of the "Global Drug-eluting Stent Market 2014-2018 with Abbott Laboratories, Boston Scientific, Medtronic & Terumo Dominating" report to their offering. One of the key drivers is the increase in the number of patients suffering from CVD. An unhealthy diet and lack of physical activity are the major factors leading to the increase in the number of people prone to CVD. Increasing demand for minimally-invasive procedures has been witnessed among members of the rapidly aging population across the world, and this is expected to boost the growth of the Global DES market. In addition, the cost efficiencies offered by less invasive methods are likely to increase the demand for the procedures in the near future. Minimally-invasive endovascular procedures are surgeries performed through minute incisions in the body. Such procedures can be used to treat plaque blockages in the arteries of the heart and other vessel walls of peripheral organs such as the kidneys and the brain. The principal advantages of these procedures over conventional surgeries are the short recovery time, the short length of the scars resulting in less physical trauma, low risk of infection, and minimized bleeding, and the shorter hospital stays associated with these surgeries. Further, the report states that the biggest challenge the market is facing is the decline in the ASP of DESs. There has been a steady decline in the prices of DESs worldwide because of the increased competition and the high rate of adoption. The reduction in the ASP has a negative impact on the overall market revenue. Key vendors dominating this space are: - Abbott Laboratories - Boston Scientific Corp - Medtronic Inc. - Terumo Corp. Other vendors mentioned in the report are: - B. Braun Melsungen AG - Biosensors International Ltd - BIOTRONIK SE & Co. KG - Cook Medical Inc. - Lepu Medical Technology Co. Ltd - MicroPort Scientific Corp. - Sorin Group USA Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Types of Drugs - Geographical Segmentation - Key Leading Countries - Rate of Incidence and Prevalence - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/c6b9zf/global
Injunction Lifted on Boston Scientific's Guidezilla - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 5:50PM CDT
Boston Scientific's Guidezilla guide extension catheter gets freed of an injunction by the U.S. Court of Appeals for the Federal Circuit.
St. Jude Medical Inc.: In-Line Is Just Not Good Enough
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
It's hard to call it a bad thing when Wall Street likes a stock, but rising expectations can create problems of their own. St. Jude Medical seems to have done a good job of selling the Street on the idea that it has turned over a new leaf and that...
FDA Clears Boston Scientific's Heart Devices - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 2:10PM CDT
Boston Scientific won the U.S. FDA approval for a bunch of defibrillators and heart failure devices.
Midday Glance: Medical Devices companies
AP - Wed Apr 16, 12:30PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
St. Jude Medical Earnings In Line, But Stock Falls
at Investor's Business Daily - Wed Apr 16, 10:31AM CDT
Device maker St. Jude Medical (STJ) met Wall Street's expectations with its Q1 results and guidance Wednesday, but the stock was down 3% in morning trading on the stock market today. St. Jude's sales rose 2% over the year-earlier quarter to $1.36...
Can Edwards Lifesciences Corp. Capitalize on This Opportunity?
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 16, 8:34AM CDT
Innovative med tech stock Edwards Lifesciences has been one of the most exciting stocks to watch in the medical device industry lately. Shares have fallen over the past year, but Edwards' battle to secure dominance in the transcatheter aortic...
Boston Scientific wins US FDA approval for new generation ICDs and CRT-Ds defibrillators and heart failure devices
M2 - Wed Apr 16, 3:02AM CDT
Medical solution company Boston Scientific (NYSE:BSX) reported on Tuesday the receipt of the US FDA's approval for its latest generation of ICDs and CRT-Ds defibrillators and heart failure devices designed to advance patient care.
BOSTON SCIENTIFIC
at Investor's Business Daily - Tue Apr 15, 5:41PM CDT
BOSTON SCIENTIFIC (BSX) received an FDA OK for its new defibrillators and heart failure devices. Shares rose 0.9%.
Boston Scientific Announces FDA Approval Of Innovative New Defibrillators And Heart Failure Devices
PR Newswire Europe - Tue Apr 15, 3:51PM CDT
Boston Scientific Corporation has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. The newly approved devices include the DYNAGEN(TM) MINI and INOGEN(TM) MINI ICDs, as well as the DYNAGEN(TM) X4 and INOGEN(TM) X4 CRT-Ds.